Visible Patient™ With Intravascular Indocyanine Green
Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being
detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly.
As such, there is a need to develop new surgical techniques to facilitate minimally invasive
pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over
lobectomy for patients presenting with early-stage lung cancer, or for patients unable to
undergo a full lobectomy due to existing comorbidities. This study will provide the first
case series using preoperative 3D anatomical planning (Visible Patient™) added to ICG and
NIF-guided robotic segmentectomy to date and will be the first reported use of Visible
Patient™-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most
frequently fatal cancer in North America, many thousands of patients will be able to benefit
from this operation every year.